Johnson & Johnson stock trades ex-dividend as Q2 sales hit record
Published on 08/25/2026 at 08:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson (US4781601046) stock entered its August 25, 2026 ex-dividend date backed by record second-quarter sales and a higher full-year 2026 outlook, highlighting how the diversified healthcare group is using steady cash returns and earnings growth to support shareholder value. Per a recent market-data overview as of August 24, 2026, JNJ shares changed hands in the upper-$270 region, leaving them significantly above their level at the start of the year and underscoring the impact of the latest quarterly results.
Dividend ex-date and yield context
An updated dividend schedule published on August 24, 2026 shows that Johnson & Johnson declared a cash dividend of $1.34 per share, with an ex-dividend date of August 25, 2026 and a payment date set for September 8, 2026. This dividend overview confirms that shareholders of record on August 25, 2026 will receive the $1.34 distribution, continuing the company’s pattern of regular quarterly payouts.
A separate exchange notice dated August 24, 2026 lists the instrument identified by ISIN US4781601046 as having its ex-dividend day on August 25, 2026 on a major European venue, aligning with the US ex-date and underlining the global coordination of the corporate action. The exchange notice reinforces that investors needed to own the stock before August 25, 2026 to qualify for the latest dividend.
From an income perspective, the $1.34 quarterly dividend implies an annualized payout of $5.36 per share. Using a recent intraday price reference of $271.00 on August 23, 2026, the indicated dividend yield stands at just under 2.0 percent, which positions the stock as a moderate-yield healthcare name compared with higher-yielding value stocks but still provides a meaningful cash component for total return. A recent pricing overview highlights that the stock traded at $267.37 at the close on August 20, 2026 and at $271.00 in trading on August 23, 2026, underscoring the linkage between the share price and the declared dividend level.
Record Q2 2026 sales and guidance raise
On the fundamentals side, Johnson & Johnson delivered a strong second quarter of 2026. According to a late-August 2026 earnings recap, the company generated sales of $25.3 billion in Q2 2026, setting a new quarterly record and representing year-over-year revenue growth of 6.6 percent. The earnings commentary notes that this performance contributed to significant share-price gains in 2026, with JNJ up close to 30 percent year-to-date by late August.
A separate valuation-focused analysis dated August 24, 2026 provides additional detail on the same quarter, stating that Johnson & Johnson’s second-quarter 2026 sales rose 6.6 percent to $25.3 billion while adjusted earnings reached $2.90 per share. This fundamental breakdown also highlights that the Innovative Medicine segment delivered operational growth of 6.8 percent in the quarter, while the MedTech division added 3.6 percent operational growth, underscoring balanced momentum across the group’s core businesses.
Management’s outlook has moved higher alongside these results. The late-August earnings recap notes that Johnson & Johnson raised both its current fiscal-year sales and adjusted EPS guidance in connection with the Q2 2026 release, and it reiterated that the company remains on track to exceed $100 billion in annual revenue in 2026 for the first time in its history. This guidance summary emphasizes that the revised sales and earnings targets underpin expectations for continued growth in the second half of 2026, even as currency and acquisition effects remain factors.
Valuation signals and year-to-date performance
For investors, the interplay between earnings momentum and valuation is an important theme. A valuation analysis updated on August 24, 2026 calculates an intrinsic value estimate of $123.97 per share for Johnson & Johnson based on a discounted-cash-flow approach, compared with a referenced market price of $270.24. The DCF-based valuation discussion concludes that at this price the stock is significantly above its modeled intrinsic value, with a negative margin of safety, and notes that several valuation models point to a similar conclusion.
The same set of valuation resources indicates that Johnson & Johnson shares changed hands near $273.31 in trading on August 24, 2026, representing an intraday gain of just over 1 percent on that session and leaving the stock 41.91 percent above one proprietary fair value estimate of $192.59. This GF Value-based analysis underscores that the combination of a defensive dividend story and strong 2026 gains has pushed the shares to a valuation level that some models consider rich relative to historical norms.
More mainstream market-data platforms provide additional perspective on the recent trend. One comprehensive stock-analysis page updated on August 24, 2026 reports that Johnson & Johnson’s stock was trading at $207.07 at the beginning of 2026 and that it has since advanced to a level just above $273 by late August 2026. This market data overview therefore measures a gain of 31.9 percent year-to-date, significantly ahead of the broader US equity benchmarks over the same period and highlighting how the combination of solid earnings and a dependable dividend has been rewarded by the market.
Regulatory catalyst in rare-disease therapy
Beyond dividends and earnings, regulatory developments provide another catalyst. A news report in French dated August 25, 2026 notes that the US Food and Drug Administration has extended the approval of a Johnson & Johnson therapy targeting a rare blood disease, broadening its treatment indication. The regulatory-approval report specifies that the decision was made public overnight and coincided with the stock trading in the low-$270s region on the New York Stock Exchange, with an indicated last price of $273.04 and a daily change of 1.04 percent in recent trading.
This extension reinforces the growth profile of Johnson & Johnson’s Innovative Medicine segment, given that rare-disease drugs often carry premium pricing and longer lifecycles. While the incremental revenue contribution from this specific label expansion has not been quantified in the cited reports, the regulatory decision underscores the company’s strategy of deepening its portfolio in specialty and rare conditions to complement its existing blockbuster therapies and offset patent-expiry risks over time.
Representative product: Stelara in inflammatory disease
Within Johnson & Johnson’s Innovative Medicine portfolio, one representative product is Stelara, a biologic therapy widely used in the treatment of inflammatory conditions such as psoriasis and certain forms of inflammatory bowel disease. Stelara’s established role in treating chronic immune-mediated diseases has made it an important driver of segment revenue and a key contributor to the company’s overall pharmaceutical sales, which include both immunology and oncology franchises. The drug’s long track record and expanding indications have also helped underpin Johnson & Johnson’s capacity to fund research on newer therapies and to sustain its quarterly dividend even as other products move through the patent cycle.
Stock level and closing context
Market-data snapshots from late August 2026 suggest that Johnson & Johnson stock was quoted in a band around the low-to-mid-$270s, with one detailed quote page showing a value of $273.11 against a reference bid of $273.04 and an indicative spread of $2.80 between buy and sell levels as of August 25, 2026, 12:59 a.m. Eastern Time. This international quote snapshot notes that prices were updated with a short delay but confirm that JNJ currently trades substantially above its 2026 starting level.
Another late-August trading summary focused on the European market records Johnson & Johnson shares at 232.550 in local-currency terms with a daily change of -0.26 percent, illustrating how the stock’s movements on secondary venues track the primary US listing while local pricing and currency dynamics can introduce small differences. The Vienna Stock Exchange update ties this quote to the same $1.34 dividend and the August 25, 2026 ex-date, reinforcing the global footprint of the shares.
For US retail investors, the key takeaway is that Johnson & Johnson stock combines a newly confirmed quarterly dividend of $1.34 per share, record second-quarter 2026 sales of $25.3 billion with 6.6 percent year-over-year growth, and a raised full-year revenue target aiming for more than $100 billion in 2026, all while the share price has climbed from $207.07 at the start of the year to the low-$270s by late August 2026. Together, these figures frame a large-cap healthcare name that currently balances income, growth and valuation considerations in a way that invites close monitoring as the year progresses.
Go deeper
More on Johnson & Johnson stock
Fact box
Company: Johnson & Johnson Inc.
ISIN: US4781601046
Ticker: JNJ
Exchange: NYSE
Price (as of August 23, 2026, 4:00 p.m. ET): $271.00 USD
Market cap: $660.0 billion (as of August 23, 2026)
Sector / Industry: Health Care / Pharmaceuticals and Medical Devices
Index membership: Dow Jones Industrial Average, S&P 500
